Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia

Circulation

Volumn 107, Issue 21, 2003, Pages 2726-2732

  Belalcazar, L Maria ^a,b   Merched, Aksam ^b   Carr, Boyd ^a   Oka, Kazuhiro ^b   Chen, Kuang Hua ^b   Pastore, Lucio ^b   Beaudet, Arthur ^b   Chan, Lawrence ^b,c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Adenovirus; Apolipoproteins; Atherosclerosis; Gene therapy; Hypercholesterolemia

Indexed keywords

APOLIPOPROTEIN A1; VASCULAR CELL ADHESION MOLECULE 1;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL DIET; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DYSLIPIDEMIA; ENDOTHELIUM CELL; FAMILIAL HYPERCHOLESTEROLEMIA; GENE OVEREXPRESSION; GENE THERAPY; GENE TRANSFER; HEART VENTRICLE REMODELING; HELPER CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM; VIRAL GENE DELIVERY SYSTEM;

EID: 0037566365     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.0000066913.69844.b2     Document Type: Article

References (34)

1. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 1995;76:69C-77C.
2. Maciejko JJ, Holmes DR, Kottke BA, et al. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med. 1983;309:385-389.
3. Miyazaki A, Sakuma S, Morikawa W, et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 1995;15:1882-1888.
4. Rubin EM, Krauss RM, Spangler EA, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265-267.
5. Paszty C, Maeda N, Verstuyft J, et al. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994;94:899-903.
6. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1994;91:9607-9611.
7. Duverger N, Kruth H, Emmanuel F, et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation. 1996;94:713-717.
8. Kochanek S, Clemens PR, Mitani K, et al. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A. 1996;93:5731-5736.
9. Parks RJ, Chen L, Anton M, et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A. 1996;93:13565-13570.
10. Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet. 1998;18:180-183.
11. Morral N, O'Neal W, Rice K, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci U S A. 1999;96:12816-12821.
12. Morral N, Parks RJ, Zhou H, et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther. 1998;9:2709-2716.
13. Kim IH, Jozkowicz A, Piedra PA, et al. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A. 2001;98:13282-13287.
14. Rubin EM, Ishida BY, Clift SM, et al. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci U S A. 1991;88:434-438.
15. Oka K, Pastore L, Kim IH, et al. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation. 2001;103:1274-1281.
16. Brousseau T, Clavey V, Bard JM, et al. Sequential ultracentrifugation micromethod for separation of serum lipoproteins and assays of lipids, apolipoproteins, and lipoprotein particles. Clin Chem. 1993;39:960-964.
17. Chen KH, Reece LM, Leary JF. Mitochondrial glutathione modulates TNF-alpha-induced endothelial cell dysfunction. Free Radic Biol Med. 1999;27:100-109.
18. Kobayashi K, Oka K, Forte T, et al. Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J Biol Chem. 1996;271:6852-6860.
19. Libby P, Li H. Vascular cell adhesion molecule-1 and smooth muscle cell activation during atherogenesis. J Clin Invest. 1993;92:538-539.
20. Cockerill GW, Rye KA, Gamble JR, et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987-1994.
21. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb. 1994;14:840-856.
22. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol. 1995;15:1512-1531.
23. Benoit P, Emmanuel F, Caillaud JM, et al. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation. 1999;99:105-110.
24. Tangirala RK, Tsukamoto K, Chun SH, et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 1999;100:1816-1822.
25. Dansky HM, Fisher EA. High-density lipoprotein and plaque regression: the good cholesterol gets even better. Circulation. 1999;100:1762-1763.
26. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262-1275.
27. Tall AR. Plasma high density lipoproteins: metabolism and relationship to atherogenesis. J Clin Invest. 1990;86:379-384.
28. Castro G, Nihoul LP, Dengremont C, et al. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Biochemistry. 1997;36:2243-2249.
29. Libby P, Sukhova G, Lee RT, et al. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol. 1995;25:S9-S12.
30. Rong JX, Li J, Reis ED, et al. Elevating high-density lipoprotein cholesterol in apolipoprotein e-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation. 2001;104:2447-2452.
31. Galis ZS. Atheroma morphology and mechanical strength: looks are important, after all. Lose the fat. Circ Res. 2000;86:1-3.
32. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
33. Moreno PR, Falk E, Palacios IF, et al. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994;90:775-778.
34. Libby P, Geng YJ, Aikawa M, et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol. 1996;7:330-335.